MapLight Therapeutics stock reaction

MapLight Therapeutics (MPLT) has drawn investor attention after recent trading, with the stock at $29.31 and showing sharp moves over the past 3 months alongside mixed short term returns.

For context, the 1-day share price return declined 1.58%, while the 90-day share price return of 66.53% and year to date share price return of 74.78% point to strong recent momentum despite a softer 30-day share price return of 4.53%.

If you are looking beyond MapLight Therapeutics, this could be a useful moment to scan the market for other opportunities in healthcare related artificial intelligence using our 40 healthcare AI stocks

With MapLight Therapeutics now at $29.31, strong recent returns and a discount of about 29% to the current analyst price target raise a key question: is there still upside here, or has the market already priced in future growth?

Preferred Price-to-Book of 3.3x: Is it justified?

On a P/B of 3.3x at a last close of $29.31, MapLight Therapeutics trades above the broader US biotech industry average of 2.6x and below its direct peer average of 4.8x.

P/B compares the company’s market value to its accounting book value, which can be a useful reference for development stage biopharmaceutical stocks that do not yet generate revenue or profits. In this case, MapLight Therapeutics has no reported revenue, is loss making with a reported net loss of $199.48m, and carries a value score of 1 out of 6, so the market is effectively putting a premium on its clinical pipeline and intellectual property rather than current earnings power.

Against the broader US biotechs industry, the 3.3x P/B looks elevated, which suggests investors are paying a higher price relative to net assets than the sector average. Compared with a peer group average of 4.8x, however, the same 3.3x P/B sits at a discount, which points to more restrained expectations when lined up against closer comparables in the space. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 3.3x (ABOUT RIGHT)

However, clinical development setbacks or weaker sentiment toward early stage, loss making biotechs could quickly challenge the current premium to book value.

Next Steps

If this mix of strong share price moves and rich multiples leaves you torn, act quickly and review the underlying data yourself. You can start with the 5 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use the tools available and keep widening your opportunity set.

• Target reliable cash generators by scanning for companies with strong payouts and resilience using the 10 dividend fortresses.
• Hunt for quality at a reasonable price by reviewing opportunities surfaced in the 46 high quality undervalued stocks.
• Strengthen your core holdings by checking stocks highlighted in the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.